Reply: Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

por van der Veldt, A A M, Boven, E, van den Eertwegh, A J M, Haanen, J B A G
Publicado 2009

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib

por van der Veldt, A A M, Meijerink, M R, van den Eertwegh, A J M, Haanen, J B A G, Boven, E
Publicado 2010

Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry

por De Groot, S., Sleijfer, S., Redekop, W. K., Oosterwijk, E., Haanen, J. B. A. G., Kiemeney, L. A. L. M., Uyl-de Groot, C. A.
Publicado 2016

Cryoablation and immunotherapy: an overview of evidence on its synergy

por Aarts, B. M., Klompenhouwer, E. G., Rice, S. L., Imani, F., Baetens, T., Bex, A., Horenblas, S., Kok, M., Haanen, J. B. A. G., Beets-Tan, R. G. H., Gómez, F. M.
Publicado 2019

Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatments

por Castenmiller, S.M., de Groot, R., Guislain, A., Monkhorst, K., Hartemink, K.J., Veenhof, A.A.F.A., Smit, E.F., Haanen, J.B.A.G., Wolkers, M.C.
Publicado 2022

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium ris...

por Haanen, J.B.A.G., Larkin, J., Choueiri, T.K., Albiges, L., Rini, B.I., Atkins, M.B., Schmidinger, M., Penkov, K., Michelon, E., Wang, J., Mariani, M., di Pietro, A., Motzer, R.J.
Publicado 2023

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

por van der Veldt, A A M, Boven, E, Helgason, H H, van Wouwe, M, Berkhof, J, de Gast, G, Mallo, H, Tillier, C N, van den Eertwegh, A J M, Haanen, J B A G
Publicado 2008

The impact of COVID-19 on oncology professionals: results of the ESMO Resilience Task Force survey collaboration

por Banerjee, S., Lim, K.H.J., Murali, K., Kamposioras, K., Punie, K., Oing, C., O'Connor, M., Thorne, E., Devnani, B., Lambertini, M., Westphalen, C.B., Garrido, P., Amaral, T., Morgan, G., Haanen, J.B.A.G., Hardy, C.
Publicado 2021

The concerns of oncology professionals during the COVID-19 pandemic: results from the ESMO Resilience Task Force survey II

por Lim, K.H.J., Murali, K., Kamposioras, K., Punie, K., Oing, C., O’Connor, M., Thorne, E., Amaral, T., Garrido, P., Lambertini, M., Devnani, B., Westphalen, C.B., Morgan, G., Haanen, J.B.A.G., Hardy, C., Banerjee, S.
Publicado 2021

The impact of COVID-19 on oncology professionals—one year on: lessons learned from the ESMO Resilience Task Force survey series

por Lim, K.H.J., Murali, K., Thorne, E., Punie, K., Kamposioras, K., Oing, C., O’Connor, M., Élez, E., Amaral, T., Garrido, P., Lambertini, M., Devnani, B., Westphalen, C.B., Morgan, G., Haanen, J.B.A.G., Hardy, C., Banerjee, S.
Publicado 2021

Unleashing NK- and CD8 T cells by combining monalizumab and trastuzumab for metastatic HER2-positive breast cancer: Results of the MIMOSA trial

por Geurts, V.C.M., Voorwerk, L., Balduzzi, S., Salgado, R., Van de Vijver, K., van Dongen, M.G.J., Kemper, I., Mandjes, I.A.M., Heuver, M., Sparreboom, W., Haanen, J.B.A.G., Sonke, G.S., Horlings, H.M., Kok, M.
Publicado 2023

LBA70_PR The impact of COVID-19 on oncology professionals: Initial results of the ESMO resilience task force survey collaboration

por Banerjee, S., Lim, K.H.J., Kamposioras, K.V., Murali, K., Oing, C., Punie, K., O'Connor, M., Devnani, B., Lambertini, M., Benedikt Westphalen, C., Garrido Lopez, P., Amaral, T.M.S., Thorne, E., Morgan, G., Haanen, J.B.A.G., Hardy, C.
Publicado 2020

1561O The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series

por Lim, K.H.J., Punie, K., Oing, C., Thorne, E., Murali, K., Kamposioras, K.V., O'Connor, M., Elez, E., Amaral, T.M.S., Lopez, P. Garrido, Lambertini, M., Devnani, B., Westphalen, C.B., Morgan, G., Haanen, J.B.A.G., Hardy, C., Banerjee, S.
Publicado 2021

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/II...

por Borgers, J. S. W., Burgers, F. H., Terveer, E. M., van Leerdam, M. E., Korse, C. M., Kessels, R., Flohil, C. C., Blank, C. U., Schumacher, T. N., van Dijk, M., Henderickx, J. G. E., Keller, J. J., Verspaget, H. W., Kuijper, E. J., Haanen, J. B. A. G.
Publicado 2022

LBA79 Dutch oncology COVID-19 Consortium (DOCC): Outcome of COVID-19 in patients with cancer in a nationwide cohort study

por de Joode, K., Dumoulin, D., Tol, J., Westgeest, H., Beerepoot, L., Van den Berkmortel, F., Mutsaers, P., van Diemen, N., Visser, O., Bloemendal, H.J., van Laarhoven, H., Hendriks, L., Haanen, J.B.A.G., de Vries, E.G.E., Dingemans, A-M.C., Van der Veldt, A.
Publicado 2020

Pharmacokinetically guided sunitinib dosing: a feasibility study in patients with advanced solid tumours

por Lankheet, N A G, Kloth, J S L, Gadellaa-van Hooijdonk, C G M, Cirkel, G A, Mathijssen, R H J, Lolkema, M P J K, Schellens, J H M, Voest, E E, Sleijfer, S, de Jonge, M J A, Haanen, J B A G, Beijnen, J H, Huitema, A D R, Steeghs, N
Publicado 2014

Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers

por Trebeschi, S, Drago, S G, Birkbak, N J, Kurilova, I, Cǎlin, A M, Delli Pizzi, A, Lalezari, F, Lambregts, D M J, Rohaan, M W, Parmar, C, Rozeman, E A, Hartemink, K J, Swanton, C, Haanen, J B A G, Blank, C U, Smit, E F, Beets-Tan, R G H, Aerts, H J W L
Publicado 2019

LBA8 Vaccination against SARS-CoV-2 in patients receiving chemotherapy, immunotherapy, or chemo-immunotherapy for solid tumors

por Oosting, S., Van der Veldt, A.A.M., GeurtsvanKessel, C.H., Fehrmann, R.S.N., van Binnendijk, R.S., Dingemans, A-M.C., Smit, E.F.F., Hiltermann, T.J.N., den Hartog, G., Jalving, M., Westphal, T., Battacharya, A., van der Heiden, M., Blank, C.U., Koopmans, M.P., van Els, C.A., Rots, N.Y., van Baarle, D., Haanen, J.B.A.G., de Vries, E.G.
Publicado 2021

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G. V., Flaherty, K. T., Stroyakovskiy, D., Gogas, H., Levchenko, E., de Braud, F., Larkin, J., Garbe, C., Jouary, T., Hauschild, A., Chiarion-Sileni, V., Lebbe, C., Mandalà, M., Millward, M., Arance, A., Bondarenko, I., Haanen, J. B. A. G., Hansson, J., Utikal, J., Ferraresi, V., Mohr, P., Probachai, V., Schadendorf, D., Nathan, P., Robert, C., Ribas, A., Davies, M. A., Lane, S. R., Legos, J. J., Mookerjee, B., Grob, J.-J.
Publicado 2017

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

por Long, G V, Flaherty, K T, Stroyakovskiy, D, Gogas, H, Levchenko, E, de Braud, F, Larkin, J, Garbe, C, Jouary, T, Hauschild, A, Chiarion-Sileni, V, Lebbe, C, Mandalá, M, Millward, M, Arance, A, Bondarenko, I, Haanen, J B A G, Hansson, J, Utikal, J, Ferraresi, V, Mohr, P, Probachai, V, Schadendorf, D, Nathan, P, Robert, C, Ribas, A, Davies, M A, Lane, S R, Legos, J J, Mookerjee, B, Grob, J -J
Publicado 2019